Announced Research Updates
Valneva announced Phase III results for their VLA1553 chikungunya vaccine.
Nektar and BMS announced results from the PIVOT IO-001 trial evaluating the effect of adding bempegaldesleukin to nivolumab in the treatment of unresectable or metastatic melanoma.
Ascendis announced results from the PaTHway trial evaluating the effect of TransCon PTH on the treatment of chronic hypoparathyroidism.
Published Research Updates
The results of a Phase II Chinese trial evaluating pyrotinib plus capecitabine in the treatment of progressive HER2-positive brain metastases after radiotherapy were published.
The results of a Phase III trial evaluating mavrilimumab plus prednisone in the treatment of giant cell arteritis were published.
A pharmacoeconomic analysis was published that used data from six Phase II trials and one Phase III trial to estimate cost-effectiveness of using MDMA-assisted therapy (MDMA-AT) to treat severe PTSD.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right